- Developing new treatments for low-grade serous ovarian cancer (2019)
The main aim of this project, led by Professor Charlie Gourley, is to develop new, more effective and targeted treatments for low-grade serous ovarian cancer. - Unlocking the power of the immune system (2018)
Led by Dr Martin Miller at the University of Cambridge, the main aim of this project is to research the immune system and its potential to transform ovarian cancer treatments. - Translating our knowledge of the DNA damage response into clinical benefits for patients with ovarian cancer (2017)
Led by Professor Richard Edmondson, this project aimed to develop a more personalised approach to treating ovarian cancer through a better understanding of the range and type of DNA damage that occurs in the disease. - Interleukin-6 as a therapeutic target in ovarian clear cell carcinoma (2016)
Led by Professor Iain Mcneish, this project looked at developing new treatments for ovarian clear cell carcinoma, a rare subtype of ovarian cancer. - EDMONd: diet and nutrition for patients with inoperable malignant bowel obstruction (2016)
The aim of the project led by Dr Agnieszka Michael was to assess whether Elemental Diet, which provides nutrition in the form of amino acids and easily digestible nutrients that are almost totally absorbed in the upper small intestine, would be tolerated by women with inoperable bowel obstruction. - Circulating tumour DNA as a specific diagnostic biomarker for ovarian cancer (2014)
Dr Elizabeth Moore led this investigation into novel methods for the earlier and more precise detection of ovarian cancer. - Personalised therapy in ovarian cancer: targeting flap structure specific endonuclease (2013)
Led by Dr Srinivasan Madhusudan, this research project looked at how to improve the effectiveness of chemotherapy by including other drugs that make the cancer cells more susceptible to damage done by the chemotherapy. - Genetic testing in epithelial ovarian cancer study (2012)
Led by Dr Marc Tischkowitz, the team wanted to see if a more streamlined model of genetic counselling alongside testing for BRCA1 and BRCA2 mutations was cost effective, feasible and acceptable to women. - Targeting microtubules to overcome resistance to chemotherapy drugs (2012)
With very few treatment options for ovarian cancer, many women become resistant to one of the two key drugs used in chemotherapy, and sadly have no other alternatives. Professor Ahmed's team looked at how microtubules are involved in resistance to paclitaxel chemotherapy. - Palliative chemotherapy to manage symptoms in women with recurrent ovarian cancer (2012)
Led by Dr Anne Lancely, this was a large, international study that aimed to predict who would benefit from chemotherapy, so as to avoid unnecessary treatment.
